Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.06.09
Views: 12620

Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital, US

ASCO press conference: Adding bevacizumab (avastin) to standard adjuvant chemotherapy does not improve disease-free survival for early-stage colon cancer

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation